Results 1 to 10 of about 5,704,490 (283)

Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive Cancers: Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer and Prostate Cancer. [PDF]

Int J Mol Sci, 2023
C-X-C motif chemokine ligand 1 (CXCL1) is a member of the CXC chemokine subfamily and a ligand for CXCR2. Its main function in the immune system is the chemoattraction of neutrophils.
Korbecki J, Bosiacki M, Barczak K, Łagocka R, Brodowska A, Chlubek D, Baranowska-Bosiacka I.   +6 more
europepmc   +2 more sources

Tamizaje del cáncer cervical

Salud Pública de México
Objetivo. Estimar las prevalencias de uso de las pruebas del Papanicolaou (Pap) y del virus del papiloma humano (VPH) antes y después del inicio de la pandemia por SARS-CoV-2. Material y métodos.
Leith Soledad León-Maldonado, Nancy López-Olmedo, Raúl Murillo, Erika Hurtado-Salgado, Betania Allen-Leigh, Alejandra Armengol-Alonso, Gabriela Torres-Mejía, Sergio Bautista-Arredondo, Tonatiuh Barrientos-Gutiérrez, Eduardo Lazcano-Ponce   +9 more
doaj   +2 more sources

Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative

Lancet Global Health, 2022
Summary Background Tracking progress and providing timely evidence is a fundamental step forward for countries to remain aligned with the targets set by WHO to eliminate cervical cancer as a public health problem (ie, to reduce the incidence of the ...
D. Singh, J. Vignat, V. Lorenzoni, Marzieh Eslahi, O. Ginsburg, B. Lauby-Secretan, M. Arbyn, P. Basu, F. Bray, S. Vaccarella   +9 more
semanticscholar   +1 more source

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Ca, 2021
This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer.
H. Sung, J. Ferlay, R. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray   +6 more
semanticscholar   +1 more source

ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

International Journal of Gynecological Cancer, 2023
In 2018, the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines for the management of patients with ...
D. Cibula, M. Raspollini, F. Planchamp, C. Centeno, Cyrus Chargari, A. Félix, D. Fischerová, Daniela Jahnn-Kuch, F. Joly, C. Kohler, S. Lax, D. Lorusso, U. Mahantshetty, P. Mathevet, R. Naik, Remi A. Nout, A. Oaknin, F. Peccatori, J. Persson, D. Querleu, S.R. Bernabé, M. Schmid, A. Stepanyan, V. Svintsitskyi, K. Tamussino, I. Zapardiel, J. Lindegaard   +26 more
semanticscholar   +1 more source

Survival with Cemiplimab in Recurrent Cervical Cancer.

New England Journal of Medicine, 2022
BACKGROUND Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1 (PD-1)-blocking antibody approved to treat lung and skin cancers, has been shown to have preliminary clinical activity in this ...
K. Tewari, B. Monk, I. Vergote, A. Miller, A. C. de Melo, H. Kim, Y. M. Kim, A. Lisyanskaya, V. Samouëlian, D. Lorusso, F. Damian, Chih-Long Chang, Evgeniy Gotovkin, S. Takahashi, D. Ramone, J. Pikiel, B. Maćkowiak-Matejczyk, E. G. Guerra Alía, N. Colombo, Y. Makarova, D. Rischin, S. Lheureux, K. Hasegawa, K. Fujiwara, Jingjin Li, Shaheda Jamil, V. Janković, Chieh-I. Chen, F. Seebach, D. Weinreich, G. Yancopoulos, I. Lowy, M. Mathias, M. Fury, A. Oaknin   +34 more
semanticscholar   +1 more source

Cancer statistics, 2023

Ca, 2023
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes using incidence data collected by central cancer ...
R. Siegel, K. Miller, N. S. Wagle, A. Jemal   +3 more
semanticscholar   +1 more source

NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.

The Journal of the National Comprehensive Cancer Network, 2023
The NCCN Guidelines for Cervical Cancer provide recommendations for all aspects of management for cervical cancer, including the diagnostic workup, staging, pathology, and treatment.
N. Abu-Rustum, C. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susan M. Campos, Junzo Chino, H. Chon, M. Crispens, S. Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli, Scott Glaser, Jordan Holmes, Brooke E Howitt, Jayanthi Lea, G. Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna B. Podoll, Kerry J Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, P. Soliman, Stefanie Ueda, Renata Urban, E. Wyse, Nicole R Mcmillian, Shaili Aggarwal, Sara Espinosa   +37 more
semanticscholar   +1 more source

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.

New England Journal of Medicine, 2021
BACKGROUND Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)-positive metastatic or unresectable cervical cancer that has progressed during chemotherapy.
N. Colombo, C. Dubot, D. Lorusso, M. V. Cáceres, K. Hasegawa, R. Shapira-Frommer, K. Tewari, P. Salman, E. Hoyos Usta, E. Yáñez, M. Gümüş, M. Olivera Hurtado de Mendoza, V. Samouëlian, V. Castonguay, A. Arkhipov, S. Toker, Kan Li, S. Keefe, B. Monk   +18 more
semanticscholar   +1 more source

Visual techniques for cervical cancer screening in Colombia

Biomédica: revista del Instituto Nacional de Salud, 2019
Introduction: Direct visual inspection for cervical cancer screening remains controversial, whereas colposcopy-biopsy is considered the gold standard for diagnosis of preneoplastic cervical lesions.
Óscar Gamboa, Mauricio González, Jairo Bonilla, Joaquín Luna, Raul Murillo, Cervical Cancer Screening Study Group INC   +5 more
doaj   +1 more source